Fig. 5

Association of baseline autoantibody profile with long-term sustained drug-free remission (DFR) in patients seropositive for anti-citrullinated protein 2 (anti-CCP2) IgG, rheumatoid factor (RF) IgM, or anti-carbamylated protein (anti-CarP) IgG at baseline (n = 336). Pairwise comparisons between each group were not significant after multiple testing (see text). a Percentage of patients with the specified number of isotypes present reaching long-term sustained DFR. The composite number of isotypes consists of the positivity count for anti-CCP2 IgG, IgM, IgA; RF IgM, IgA; and anti-CarP IgG, IgM, IgA. Due to the technical success rate of isotype measurements, and some seropositive patients testing negative upon re-measurement (see Additional file 1: Figure S1), the total number of patients included in a is 309. b Percentage of patients with the specified number of anti-modified protein antibodies (AMPAs) present reaching long-term sustained DFR. The composite number of AMPAs consists of the positivity count for anti-CCP2 IgG, anti-CarP IgG, anti-citrullinated-vimentin 59-74 IgG, anti-citrullinated-fibrinogen β 36-52 IgG and α 27-43 IgG, anti-citrullinated-enolase 5-20 IgG, anti-acetylated-lysine IgG, and anti-acetylated-ornithine IgG. Thirty-six patients were RF IgM positive but had no AMPA antibodies (not shown). c Percentage of patients with the specified number of antibodies present reaching long-term sustained DFR. Anti-cit. pept. Abs, anti-citrullinated peptide antibodies; Anti-acetyl. pept. Abs, anti-acetylated peptide antibodies